Clinical Trial Update: Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Peginterferon alfa-2b in HBeAg-positive chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Chronic Hepatitis B | Phase 3 | Status: COMPLETED